Pros | ![]() Beats FD returns for both 3Y & 5Y duration. | ![]() Beats FD returns for both 3Y & 5Y duration. | ||
Cons | ![]() 5Y returns in the bottom 25% of the category. | ![]() 5Y returns in the bottom 25% of the category. ![]() 3Y returns in the bottom 25% of the category. |
INDMoney rank | 3/8 | 8/8 | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 9 Years | 5 Years | ||
Fund Size | 1184 Cr | 815 Cr | ||
Min Investment | SIP ₹100 Lumpsum ₹5000 | SIP ₹100 Lumpsum ₹1000 | ||
Expense Ratio | 0.72% | 1.1% | ||
Exit Load | 0.25% | 1% | ||
Benchmark Index | Nifty Pharma TR INR | BSE Healthcare TR INR |
No of Holdings | 41 | 29 | ||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (11.79%) Aurobindo Pharma Ltd (7.27%) Cipla Ltd (5.97%) Apollo Hospitals Enterprise Ltd (5.66%) Lupin Ltd (5.2%) | Sun Pharmaceuticals Industries Ltd (14.49%) Cipla Ltd (8.9%) Torrent Pharmaceuticals Ltd (7.6%) Abbott India Ltd (6.56%) Apollo Hospitals Enterprise Ltd (5.93%) | ||
No of Sectors | 2 | 2 | ||
Top 3 Sectors | Health (97.56%) Basic Materials (2.44%) | Health (99.2%) Basic Materials (0.8%) | ||
Equity % | 95.76% | 98.62% | ||
Debt % | - | - | ||
P/E | 34.41 | 35.29 | ||
P/B | 4.98 | 5.9 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | 4.99% | 4.21% | ||
3-Month Return | -3.75% | -3.19% | ||
6-Month Return | -8.15% | -9.71% | ||
1-Year Return | 17.07% | 14.09% | ||
3-Year Return | 20.02% | 18.06% | ||
5-Year Return | 23.79% | 21.4% |
Sharpe | 0.81 | 0.74 | ||
Alpha | 3.47 | -0.56 | ||
Beta | 0.95 | 0.96 | ||
Standard Deviation | 16.85 | 16.88 | ||
Information Ratio | 1.13 | -0.34 |
Description | Tata India Pharma & Healthcare Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Meeta Shetty | Dhaval Shah |